275 related articles for article (PubMed ID: 31391581)
1. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
Rao GK; Makani VKK; Mendonza JJ; Edathara PM; Patel N; Ramakrishna M; Cilamkoti P; Chiring Phukon J; Jose J; Bhadra U; Bhadra MP
FEBS J; 2022 May; 289(10):2915-2934. PubMed ID: 34854238
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
[TBL] [Abstract][Full Text] [Related]
4. Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV; Zentner GE
Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
[TBL] [Abstract][Full Text] [Related]
5. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
[TBL] [Abstract][Full Text] [Related]
6. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
7. Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.
Berko ER; Mossé YP
Cancer Cell; 2019 Oct; 36(4):345-347. PubMed ID: 31614113
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
9. CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention.
Pugacheva EM; Kubo N; Loukinov D; Tajmul M; Kang S; Kovalchuk AL; Strunnikov AV; Zentner GE; Ren B; Lobanenkov VV
Proc Natl Acad Sci U S A; 2020 Jan; 117(4):2020-2031. PubMed ID: 31937660
[TBL] [Abstract][Full Text] [Related]
10. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
[TBL] [Abstract][Full Text] [Related]
11. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
12. BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
Pugacheva EM; Bhatt DN; Rivero-Hinojosa S; Tajmul M; Fedida L; Price E; Ji Y; Loukinov D; Strunnikov AV; Ren B; Lobanenkov VV
Genome Biol; 2024 Jan; 25(1):40. PubMed ID: 38297316
[TBL] [Abstract][Full Text] [Related]
13. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
[TBL] [Abstract][Full Text] [Related]
14. The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.
Trigg RM; Lee LC; Prokoph N; Jahangiri L; Reynolds CP; Amos Burke GA; Probst NA; Han M; Matthews JD; Lim HK; Manners E; Martinez S; Pastor J; Blanco-Aparicio C; Merkel O; de Los Fayos Alonso IG; Kodajova P; Tangermann S; Högler S; Luo J; Kenner L; Turner SD
Nat Commun; 2019 Nov; 10(1):5428. PubMed ID: 31780656
[TBL] [Abstract][Full Text] [Related]
15. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
16.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
17. Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions.
Pugacheva EM; Rivero-Hinojosa S; Espinoza CA; Méndez-Catalá CF; Kang S; Suzuki T; Kosaka-Suzuki N; Robinson S; Nagarajan V; Ye Z; Boukaba A; Rasko JE; Strunnikov AV; Loukinov D; Ren B; Lobanenkov VV
Genome Biol; 2015 Aug; 16(1):161. PubMed ID: 26268681
[TBL] [Abstract][Full Text] [Related]
18. CTCF and BORIS in genome regulation and cancer.
Marshall AD; Bailey CG; Rasko JE
Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
[TBL] [Abstract][Full Text] [Related]
19. The evolution of epigenetic regulators CTCF and BORIS/CTCFL in amniotes.
Hore TA; Deakin JE; Marshall Graves JA
PLoS Genet; 2008 Aug; 4(8):e1000169. PubMed ID: 18769711
[TBL] [Abstract][Full Text] [Related]
20. CTCFL/BORIS is a methylation-independent DNA-binding protein that preferentially binds to the paternal H19 differentially methylated region.
Nguyen P; Cui H; Bisht KS; Sun L; Patel K; Lee RS; Kugoh H; Oshimura M; Feinberg AP; Gius D
Cancer Res; 2008 Jul; 68(14):5546-51. PubMed ID: 18632606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
